Stromal biomarker-based framework for identifying pMMR/MSS and dMMR/MSI colorectal cancers with poor outcomes and limited benefit from immunotherapy
Por:
Coma, MI, Badia-Ramentol, J, Martinez-Ciarpaglini, C, Linares, J, Tarazona, N, Mulet-Margalef, N, Tornero-Piñero, P, Sallent-Aragay, A, Recort-Bascuas, A, Gibert, J, Sant-Albors, M, Tauriello, DVF, Cruz-Moral, M, Carreras-Gallardo, M, Sancho, E, Martinez, CM, Garrido, M, Mozo, JLM, Cervantes, A, Montagut, C, Batlle, E and Calon, A
Publicada:
14 abr 2026
Ahead of Print:
1 abr 2026
Resumen:
Background Colorectal cancer (CRC) remains a leading cause of cancer mortality worldwide, with clinical progress limited by intratumoural cellular diversity and the absence of robust, informative markers.Objective Leveraging the heterogeneity of cancer-associated fibroblasts (CAFs) within the tumour microenvironment, this study aims to identify and evaluate candidate biomarkers to support patient stratification and improve prediction of therapeutic responses.Design We applied a multiomic approach integrating single-cell RNA sequencing, computational cell deconvolution and protein-level assessment from patient tumours, complemented by in vitro and in vivo preclinical models, to characterise stromal populations linked to CRC progression and treatment resistance.Results Retrospective analysis of over 3000 patient samples across multiple cohorts identified a distinct subset of CAFs expressing collagen triple helix repeat containing 1 (CTHRC1). CTHRC1(+) CAFs were associated with increased transforming growth factor-beta (TGF-beta) signalling and poor clinical outcomes in early and advanced disease stages. CTHRC1(+) CAFs enabled stratification of both mismatch repair-deficient/microsatellite instability (dMMR/MSI) and mismatch repair-proficient/microsatellite stability (pMMR/MSS) tumours into immune-inflamed and poorly immunogenic subtypes. Retrospective analysis of several clinical trials revealed that CTHRC1(+) CAFs are linked to resistance to immune checkpoint inhibitors in MSI and MSS tumours, suggesting therapeutic potential for combining TGF-beta blockade with immunotherapy.Conclusion CTHRC1-expressing CAFs represent clinically relevant biomarkers that link molecular profiling with diagnostic pathology. Our findings support the potential incorporation of CTHRC1(+) CAF assessment into routine histopathological workflows, pending prospective validation, and suggest a framework for stroma-informed CRC stratification, particularly in patients with stroma-rich, treatment-resistant tumours and pMMR/MSS with limited therapeutic options.
Filiaciones:
Coma, MI:
Hosp del Mar, Dept Pathol, Barcelona, Spain
Hosp del Mar Res Inst HMRIB, Canc Res Program, Barcelona, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
Badia-Ramentol, J:
Hosp del Mar Res Inst HMRIB, Canc Res Program, Barcelona, Spain
Martinez-Ciarpaglini, C:
Univ Valencia, Hosp Clin Univ, Dept Pathol, Valencia, Spain
INCLIVA Biomed Res Inst, Valencia, Spain
Linares, J:
Hosp del Mar Res Inst HMRIB, Canc Res Program, Barcelona, Spain
Hosp del Mar, Dept Med Oncol, Barcelona, Spain
Tarazona, N:
Inst Salud Carlos III, Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
INCLIVA Biomed Res Inst, Valencia, Spain
Univ Valencia, Hosp Clin Univ, Dept Med Oncol, Valencia, Spain
:
Catalan Inst Oncol ICO Badalona, Dept Med Oncol, Badalona, Spain
Germans Trias & Pujol Res Inst IGTP, Badalona, Spain
Tornero-Piñero, P:
Hosp del Mar, Dept Pathol, Barcelona, Spain
Sallent-Aragay, A:
Hosp del Mar Res Inst HMRIB, Canc Res Program, Barcelona, Spain
Recort-Bascuas, A:
Hosp del Mar Res Inst HMRIB, Canc Res Program, Barcelona, Spain
Gibert, J:
Hosp del Mar Res Inst HMRIB, Canc Res Program, Barcelona, Spain
Sant-Albors, M:
Hosp del Mar Res Inst HMRIB, Canc Res Program, Barcelona, Spain
Tauriello, DVF:
Barcelona Inst Sci & Technol BIST, Inst Res Biomed IRB Barcelona, Barcelona, Spain
Univ Med Ctr, Erasmus MC Canc Inst, Dept Med Oncol, Rotterdam, Netherlands
Cruz-Moral, M:
Hosp del Mar Res Inst HMRIB, Canc Res Program, Barcelona, Spain
Carreras-Gallardo, M:
Hosp del Mar Res Inst HMRIB, Canc Res Program, Barcelona, Spain
Sancho, E:
Inst Salud Carlos III, Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
Barcelona Inst Sci & Technol BIST, Inst Res Biomed IRB Barcelona, Barcelona, Spain
Martinez, CM:
Barcelona Inst Sci & Technol BIST, Inst Res Biomed IRB Barcelona, Barcelona, Spain
Garrido, M:
Hosp del Mar Res Inst HMRIB, Canc Res Program, Barcelona, Spain
:
Catalan Inst Oncol ICO Badalona, Dept Med Oncol, Badalona, Spain
Germans Trias & Pujol Res Inst IGTP, Badalona, Spain
Cervantes, A:
Inst Salud Carlos III, Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
INCLIVA Biomed Res Inst, Valencia, Spain
Univ Valencia, Hosp Clin Univ, Dept Med Oncol, Valencia, Spain
Montagut, C:
Hosp del Mar Res Inst HMRIB, Canc Res Program, Barcelona, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
Hosp del Mar, Dept Med Oncol, Barcelona, Spain
Pompeu Fabra Univ, Barcelona, Spain
Batlle, E:
Inst Salud Carlos III, Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
Barcelona Inst Sci & Technol BIST, Inst Res Biomed IRB Barcelona, Barcelona, Spain
Inst Catalana Recerca & Estudis Avancats ICREA, Barcelona, Spain
Calon, A:
Hosp del Mar Res Inst HMRIB, Canc Res Program, Barcelona, Spain
hybrid
|